Published in:
01-02-2012 | Letter
Passive immunotherapy of sepsis with intravenous immune globulin: not all IVIg preparations are created equal
Authors:
Tchavdar Vassilev, Michael Bauer
Published in:
Critical Care
|
Issue 1/2012
Login to get access
Excerpt
Normal intravenous immunoglobulin (IVIg) preparations are known to neutralize a wide array of pathogens plus their virulence factors and in addition possess broad anti-inflammatory and immunomodulating activities. However, these preparations have not been really successful in their present form in preventing sepsis-related death. The recent report by the International Neonatal Immunotherapy Study Collaborative Group is the account of the last in a series of clinical trials that have failed to show an effect of IVIg administration on sepsis outcome [
1]. Each batch of IVIgs is produced by fractionation of a plasma pool obtained from at least 10,000 healthy donors. All these studies have used different immunoglobulin preparations assuming that their properties are identical as the IgG repertoire in them is representative for a large population of healthy plasma donors. …